Lonza: Starts 2017 With Outstanding First Quarter.

25 Apr 2017 - ShareInvestor Express
Strong start in Q1 paves way for double-digit organic sales growth for first half year. CORE EBIT growth expected to be even stronger than sales growth for first half of 2017. Pharma&Biotech with strong performance in revenue and profitability. Specialty Ingredients with robust growth and profitability ...
sgx:o6z

---

Lonza: Successfully Places 5 Million New Shares, Raising Gross Proceeds Of CHF865 Million.

1 Feb 2017 - ShareInvestor Express
Lonza Group AG has successfully placed 5.0 million new shares by way of an accelerated bookbuilding procedure with selected investors in Switzerland and outside of Switzerland to institutional investors and qualified institutional buyers, in reliance on Regulation S and 144A of the U.S. Securities Act...
sgx:o6z

---

Lonza: Announces The Launch Of An Accelerated Bookbuilding.

1 Feb 2017 - ShareInvestor Express
Following the announcement on 15 December 2016 regarding the contemplated acquisition of Capsugel S.A. by Lonza Group AG, Lonza launches an accelerated bookbuilding by offering up to 5.0 million registered shares, sourced from authorised capital. As a result, Lonza's share capital will increase by a ...
sgx:o6z

---

Lonza: Appoints Fridtjof Helemann, CHRO, To Executive Committee.

25 Jan 2017 - ShareInvestor Express
Lonza's Board of Directors announced the appointment of Fridtjof Helemann, Chief Human Resources Officer for Lonza, as a member of the Executive Committee, responsible for Human Resources, Communications and Environment, Health and Safety, effective 1 February 2017. Fridtjof Helemann (1954) joined Lonza ...
sgx:o6z

---

Lonza: Reports Record-Breaking Financial Performance, Resulting In 24.2% CORE EBIT Growth, Driven By Pharma&Biotech.

25 Jan 2017 - ShareInvestor Express
Strong sales growth of 8.7% to CHF 4.13 billion. Excellent CORE EBIT of CHF 651 million, up by 24.2%. CORE RONOA improvement of 500 bps, reaching 21.5%. Another solid year of operational free cash flow of CHF 638 million before acquisitions. Remarkable Pharma&Biotech sales growth of 15.9%, leading to ...
sgx:o6z

---

Lonza: Concludes Divestment Of Peptides Business & Operations In Braine-l'Alleud, Belgium, To PolyPeptide.

4 Jan 2017 - ShareInvestor Express
Lonza has concluded the divestment of its Peptides Business located in Braine-l'Alleud, to PolyPeptide Laboratories Holding. The facility, with approximately 280 employees, was the center for peptide chemical development and manufacturing within Lonza. The intention to divest was announced at the beginning ...
sgx:o6z

---

Lonza: To Acquire Capsugel To Create Leading Integrated Solutions Provider To The Global Pharma & Consumer Healthcare Industries.

15 Dec 2016 - ShareInvestor Express
Lonza to acquire Capsugel for USD 5.5 billion, including refinancing of existing Capsugel debt of USD ~2 billion. Acquisition is expected to accelerate Lonza's growth and ability to deliver value along the healthcare continuum. Acquisition addresses needs of customers for integrated, value-added solutions ...
sgx:o6z

---

Singapore: Lonza Group to acquire Capsugel from KKR in $5.5b deal

15 Dec 2016 - DealStreetAsia
Lonza Group AG, which is listed on the SIX Swiss Exchange and maintains a secondary listing on the Singapore Exchange (SGX), is acquiring Capsugel from KKR for a consideration of $5.5 billion in cash, including refinancing of existing Capsugel debt of approximately $2 billion,. The transaction will be ...
sgx:o6z

---

Lonza: Confirms Interest In Capsugel.

12 Dec 2016 - ShareInvestor Express
Lonza Group Ltd notes the recent press speculations that it is in final negotiations with KKR regarding the potential acquisition of Capsugel. Lonza confirms that it has expressed a strong interest in this successful company as it would fit perfectly with Lonza's Healthcare Continuum strategy and strengthen ...
sgx:o6z

---

Lonza: To Divest Peptides Business & Operations In Braine-l'Alleud, Belgium, To PolyPeptide.

7 Dec 2016 - ShareInvestor Express
Lonza and the PolyPeptide Group jointly announced that PolyPeptide Laboratories Holding has entered into a definitive agreement with Lonza Sales AG and Lonza AG, both 100% affiliates of Lonza Group AG, to acquire the peptides business and operations of Lonza in Braine-l'Alleud, Belgium. Lonza's Braine ...
sgx:o6z

---